Accretion Pharmaceuticals Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Net Income	67.94	14.93	1.04	0.79
Depreciation & Amortization	7.75	2.24	9.23	8.1
Other Operating Activities	25.5	16.9	10.76	10.35
Change in Accounts Receivable	-58.57	-70.47	-17.31	12.55
Change in Inventory	-61.34	-144.76	-8.31	-19.75
Change in Accounts Payable	10.09	66.08	11.12	5.71
Change in Other Net Operating Assets	66.14	-	-3.32	3.74
Operating Cash Flow	57.5	-115.09	3.21	21.5
Operating Cash Flow Growth	-	-	-85.06%	-
Capital Expenditures	-16.11	-54.78	-11.78	-2.57
Sale of Property, Plant & Equipment	-	-	0.79	-
Investing Cash Flow	-16.11	-54.78	-11	-2.57
Long-Term Debt Issued	-	134.78	8.58	-
Long-Term Debt Repaid	-57.43	-	-	-2.81
Net Debt Issued (Repaid)	-57.43	134.78	8.58	-2.81
Issuance of Common Stock	30	40	6.59	-
Repurchase of Common Stock	-	-	-	-2.87
Other Financing Activities	-14.37	-3.99	-10.76	-10.17
Financing Cash Flow	-41.8	170.79	4.4	-15.85
Miscellaneous Cash Flow Adjustments	0	-	-	-0
Net Cash Flow	-0.41	0.92	-3.38	3.08
Free Cash Flow	41.39	-169.87	-8.57	18.93
Free Cash Flow Margin	7.21%	-127.22%	-2.90%	8.38%
Free Cash Flow Per Share	5.16	-22.35	-	-
Cash Interest Paid	14.37	3.99	10.76	10.17
Cash Income Tax Paid	18.58	-7.89	0.35	0.07
Levered Free Cash Flow	-43.95	-111.16	-19.15	-
Unlevered Free Cash Flow	-35.28	-109.56	-12.74	-
Change in Working Capital	-43.68	-149.15	-17.82	2.26

Source: S&P Global Market Intelligence. Standard template. Financial Sources.